Novavax Global Commercial Operations and COVID-19 Vaccine Update

Study 311: Demographics and baseline characteristics NK BA.1 Vaccine (N = 279) Prototype Vaccine (N = 273) Bivalent Vaccine (N = 277) Age (years) - median (range) 42.0 (18-64) 41.0 (18-64) 41.0 (18-64) Female 53.4% 52.0% 56.3% Race White 81% 78.4% 82.3% Asian 13.3% 16.5% 14.1% Other 2.9% 2.9% 2.2% Median interval to boost (Days) 177.0 182.0 180.0 Previous vaccine Pfizer x 3 75.6% 78.0% 73.3% Previous vaccine Pfizer x 2, Moderna 23.3% 20.5% 24.5% Anti-N or PCR positive 49.5% 52.4% 50.5% novavax © 2023 NOVAVAX. All rights reserved. 53

View entire presentation